deltatrials
Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06461897

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up)

A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Sponsor: AbbVie

Conditions Atopic Dermatitis
Interventions Dupilumab Upadacitinib
Updated 19 times since 2024 Last updated: Feb 26, 2026 Started: Aug 19, 2024 Primary completion: Jul 31, 2030 Completion: Jul 31, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06461897, this PHASE3 trial focuses on Atopic Dermatitis and remains actively recruiting participants. Sponsored by AbbVie, it has been updated 19 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Feb 2025 · 2 months · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – ~Jan 2026 · 31 days · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 4 months · monthly snapshot

Change History

19 versions recorded

  1. Mar 2026 — Present [monthly]

    Recruiting PHASE3

  2. Feb 2026 — Mar 2026 [monthly]

    Recruiting PHASE3

  3. Jan 2026 — Feb 2026 [monthly]

    Recruiting PHASE3

  4. Dec 2025 — Jan 2026 [monthly]

    Recruiting PHASE3

  5. Nov 2025 — Dec 2025 [monthly]

    Recruiting PHASE3

▶ Show 14 earlier versions

  1. Oct 2025 — Nov 2025 [monthly]

    Recruiting PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE3

  3. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE3

  4. Jul 2025 — Aug 2025 [monthly]

    Recruiting PHASE3

  5. Jun 2025 — Jul 2025 [monthly]

    Recruiting PHASE3

  6. May 2025 — Jun 2025 [monthly]

    Recruiting PHASE3

  7. Apr 2025 — May 2025 [monthly]

    Recruiting PHASE3

  8. Mar 2025 — Apr 2025 [monthly]

    Recruiting PHASE3

  9. Feb 2025 — Mar 2025 [monthly]

    Recruiting PHASE3

  10. Dec 2024 — Feb 2025 [monthly]

    Recruiting PHASE3

  11. Nov 2024 — Dec 2024 [monthly]

    Recruiting PHASE3

  12. Oct 2024 — Nov 2024 [monthly]

    Recruiting PHASE3

  13. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  14. Jul 2024 — Sep 2024 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Afula, Israel , Amiens, France , Amsterdam, Netherlands , Ansan-si, South Korea , Argenteuil, France , Arlington, United States , Bad Bentheim, Germany , Bayamón, Puerto Rico , Beersheba, Israel , Beijing, China and 116 more locations